Ann: Quarterly Activity Report & Appendix 4C, page-42

This last quarter was the first full quarter under the BH deal and the ones before were running down stock on the old OZ distribution deal and pre BH launch in USA.

I've heard a couple of family offices are buying some units in OCC, could be the pick up in volume of late. Word is getting out that OCC has some value and rising revenues.

Slow burn here but once we get the Nerve product approved in USA by the end of next year and a distribution deal/cash injection the share price won't be around these levels.

ATI read out results next cab off the rank from memory due end of next month.

OCC needs less retail holders and more long term holders with a chunk of the stock. It's too loosely held by retail hence the price moving on low volumes each year.